"Take a Closer Look", page-1048

I paid a premium for AHZ in the past. I was attracted by the "story", i gave too much merit to qualitative measures of company performance (and was mistaken), and i failed to consider all aspects of the company before appraising its likelihood of success, and finally its value. I also massively underestimated the time it takes for new products to gain traction in new markets.
I overpaid for my initial purchase(s). No doubt.

I recently purchased at $0.33, $0.31, & $0.265, and i am more than comfortable with the price paid. Although valuing a company such as AHZ at its current stage is difficult and fraught with danger (as evidenced by the numerous "analyst" reports that have proven to be complete garbage), i feel that the "premium" at this level is completely justifiable.

- 50%+ revenue growth is worth paying a premium for
- Management who cut OPEX by 25% are worth paying a premium for
- 68% Gross margins (and growing) are worth paying a premium for
- Global talent recruited from the worlds largest and most successful Pharma & Bio-Tech companies are worth paying a premium for.

Besides which, if my projections (which are far more conservative than the stated 2020 targets) are in the ballpark, we are currently paying 13.5 x FY19 Earnings for the company.

If i had my time again i would have been more patient, smarter, less influenced by investment biases etc etc. With todays SP though, and the currently available information, AHZ is most definitely a BUY - and worth paying a small premium for.